[{"id":"4756adfb-fbb9-43c4-b721-699340b15b57","date":"2005","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2005","revenue":18308.8,"net_profit":1936.49,"investments":933.23,"firms":190,"profitable_firms":174,"profit_margin":0.10576826444114307,"profitable_share":0.9157894736842105,"bank_debt":894.7,"total_liab":3677.5,"leverage_bank_to_rev":0.04886721139561304,"leverage_tot_to_rev":0.20085969588394653,"invest_intensity":0.0509716638993271,"cagr_revenue":null,"cagr_net_profit":null,"cagr_investments":null,"cagr_firms":null,"profit_margin_std_3y":null,"size_index":1.3439448540429226,"growth_index":null,"profit_index":95.79573875932763,"risk_index":64.16665886495844,"outlook_index":2.1611516106898847,"current_index":43.46772132012802,"future_index":20.114458303763485,"main_index":34.12641611358221,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"04fa8bfa-bb98-49f4-821d-d69cdccef0ff","date":"2006","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2006","revenue":19539.24,"net_profit":1993.56,"investments":964.98,"firms":196,"profitable_firms":172,"profit_margin":0.10202853335134836,"profitable_share":0.8775510204081632,"bank_debt":1419.98,"total_liab":5590.32,"leverage_bank_to_rev":0.07267324624703929,"leverage_tot_to_rev":0.28610734092011764,"invest_intensity":0.049386772464026236,"cagr_revenue":null,"cagr_net_profit":null,"cagr_investments":null,"cagr_firms":null,"profit_margin_std_3y":0.0026443892134080014,"size_index":1.3322321973757374,"growth_index":null,"profit_index":71.1701529210648,"risk_index":95.8946406505685,"outlook_index":1.9636755852754362,"current_index":46.8273768649119,"future_index":29.553862429280727,"main_index":39.917971090659435,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"81c4a2cc-aa18-4114-8b7c-4b96a3490ba2","date":"2007","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2007","revenue":20560.85,"net_profit":1785.83,"investments":1164.15,"firms":194,"profitable_firms":170,"profit_margin":0.08685584496749892,"profitable_share":0.8762886597938144,"bank_debt":2674.0600000000004,"total_liab":6620.35,"leverage_bank_to_rev":0.13005590722173455,"leverage_tot_to_rev":0.32198814737717557,"invest_intensity":0.056619740915380454,"cagr_revenue":null,"cagr_net_profit":null,"cagr_investments":null,"cagr_firms":null,"profit_margin_std_3y":0.010015618401314121,"size_index":1.2673657468984434,"growth_index":null,"profit_index":85.81657832310309,"risk_index":93.34206720886777,"outlook_index":2.0803287773658896,"current_index":49.7102378928158,"future_index":28.83475167360669,"main_index":41.36004340513215,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"5bccfd94-fa80-46b0-a34c-db6f4a0ea9d0","date":"2008","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2008","revenue":23227.88,"net_profit":2053.75,"investments":1347.86,"firms":194,"profitable_firms":170,"profit_margin":0.08841745350845621,"profitable_share":0.8762886597938144,"bank_debt":2364.08,"total_liab":6961.219999999999,"leverage_bank_to_rev":0.1017776912916719,"leverage_tot_to_rev":0.2996924385695121,"invest_intensity":0.0580276805287439,"cagr_revenue":0.08255481920708907,"cagr_net_profit":0.019790055451396116,"cagr_investments":0.13036498989404177,"cagr_firms":0.006968865952445835,"profit_margin_std_3y":0.008345763281631538,"size_index":1.2320422203450776,"growth_index":72.21463239638196,"profit_index":86.19994095709862,"risk_index":95.42783742873608,"outlook_index":22.869321587515234,"current_index":68.47840301105998,"future_index":59.44046958254151,"main_index":64.86322963965259,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"8f31f277-d4ea-4a2d-8061-9af3ce7381ee","date":"2009","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2009","revenue":28266.6,"net_profit":1552.12,"investments":1122.08,"firms":210,"profitable_firms":174,"profit_margin":0.05491003516517728,"profitable_share":0.8285714285714286,"bank_debt":2071.23,"total_liab":7154.990000000001,"leverage_bank_to_rev":0.07327481904438454,"leverage_tot_to_rev":0.2531252432199133,"invest_intensity":0.039696320038490655,"cagr_revenue":0.1309809816226033,"cagr_net_profit":-0.08004766090716309,"cagr_investments":0.051562692499034224,"cagr_firms":0.023264108093813185,"profit_margin_std_3y":0.018910845517818627,"size_index":1.4932088555589182,"growth_index":33.033961275117036,"profit_index":57.32670235767858,"risk_index":95.54539486357216,"outlook_index":19.652440570018946,"current_index":51.55242613838233,"future_index":46.43478306961434,"main_index":49.505368910875134,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"616b9ccf-7998-44b5-89b3-bcf3e8ed50eb","date":"2010","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2010","revenue":31873.12,"net_profit":3023.39,"investments":1332.44,"firms":212,"profitable_firms":164,"profit_margin":0.09485704568614557,"profitable_share":0.7735849056603774,"bank_debt":1694.17,"total_liab":9681.64,"leverage_bank_to_rev":0.05315356639073929,"leverage_tot_to_rev":0.303755641117029,"invest_intensity":0.04180450486177695,"cagr_revenue":0.157340553114514,"cagr_net_profit":0.1918401711885349,"cagr_investments":0.04603505692431442,"cagr_firms":0.030017753536526248,"profit_margin_std_3y":0.02144752930995711,"size_index":1.566888124312902,"growth_index":67.75148405551418,"profit_index":69.69038200316479,"risk_index":94.60911874073462,"outlook_index":26.552232213701373,"current_index":63.0565797617527,"future_index":59.32907372435519,"main_index":61.565577346793695,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"37d1982b-b102-41ff-b1e8-538e97fce404","date":"2011","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2011","revenue":25604.8,"net_profit":1489.24,"investments":1090.15,"firms":200,"profitable_firms":154,"profit_margin":0.05816253202524527,"profitable_share":0.77,"bank_debt":3434.9399999999996,"total_liab":8384.939999999999,"leverage_bank_to_rev":0.1341521902143348,"leverage_tot_to_rev":0.32747531712803846,"invest_intensity":0.04257600137474224,"cagr_revenue":0.03300860223291524,"cagr_net_profit":-0.10159456196260341,"cagr_investments":-0.06829056944033796,"cagr_firms":0.010204786449813152,"profit_margin_std_3y":0.022184190009242703,"size_index":1.2411047479820172,"growth_index":45.02401007429583,"profit_index":82.17439709405124,"risk_index":94.96031468042351,"outlook_index":12.528558184766808,"current_index":60.53591714581022,"future_index":47.00672070032252,"main_index":55.12423856761514,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"2eb92aa8-e72e-418c-8b4b-1fdf0211530e","date":"2012","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2012","revenue":27981.34,"net_profit":1696.5700000000002,"investments":912.7,"firms":210,"profitable_firms":160,"profit_margin":0.06063219273987594,"profitable_share":0.7619047619047619,"bank_debt":5161.51,"total_liab":9865.42,"leverage_bank_to_rev":0.18446257398680693,"leverage_tot_to_rev":0.3525713922206728,"invest_intensity":0.032618166249364755,"cagr_revenue":-0.0033753028797469664,"cagr_net_profit":0.03010658329719007,"cagr_investments":-0.06652775480291839,"cagr_firms":0,"profit_margin_std_3y":0.020509863952292044,"size_index":1.2700070920244468,"growth_index":15.52546996380054,"profit_index":67.10252829052929,"risk_index":94.82570064389152,"outlook_index":4.112490294999401,"current_index":49.3587111751548,"future_index":34.75034730030738,"main_index":43.515365625215836,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"285c6e55-b980-467e-b1b3-87da2664f745","date":"2013","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2013","revenue":30448.61,"net_profit":4592.46,"investments":724.72,"firms":208,"profitable_firms":176,"profit_margin":0.15082658945679295,"profitable_share":0.8461538461538461,"bank_debt":4255.8,"total_liab":9330.130000000001,"leverage_bank_to_rev":0.1397699271001205,"leverage_tot_to_rev":0.30642219792627645,"invest_intensity":0.02380141490859517,"cagr_revenue":-0.015125337676961781,"cagr_net_profit":0.14952142464213813,"cagr_investments":-0.1837167938251253,"cagr_firms":-0.006329283488911153,"profit_margin_std_3y":0.05280112997978226,"size_index":1.3095133367105651,"growth_index":23.29240920484031,"profit_index":84.61698719501422,"risk_index":93.35684925262575,"outlook_index":2.1104614838904343,"current_index":55.24630654309347,"future_index":35.83896213079599,"main_index":47.48336877817448,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"30f5b418-981f-412a-9d4a-219cbed4e339","date":"2014","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2014","revenue":30894.120000000003,"net_profit":2632.2,"investments":792.82,"firms":210,"profitable_firms":176,"profit_margin":0.08520067896415238,"profitable_share":0.8380952380952381,"bank_debt":3426.76,"total_liab":8306.2,"leverage_bank_to_rev":0.11091948888655835,"leverage_tot_to_rev":0.2688602232398916,"invest_intensity":0.02566248852532456,"cagr_revenue":0.06459595997654977,"cagr_net_profit":0.20906986642321068,"cagr_investments":-0.10071756091171213,"cagr_firms":0.01639635681485352,"profit_margin_std_3y":0.04662867473002198,"size_index":1.3124985846507498,"growth_index":9.982617587873213,"profit_index":87.80015997247796,"risk_index":88.17085855532507,"outlook_index":10.151788200123132,"current_index":51.159451673615465,"future_index":33.50675812300874,"main_index":44.098374253372775,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"0779fc69-bd47-4459-8d6f-285d897866c7","date":"2015","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2015","revenue":34088.83,"net_profit":1573.33,"investments":1160.66,"firms":218,"profitable_firms":178,"profit_margin":0.046153828101463144,"profitable_share":0.8165137614678899,"bank_debt":3509.28,"total_liab":10007.08,"leverage_bank_to_rev":0.1029451582820531,"leverage_tot_to_rev":0.2935589165131217,"invest_intensity":0.03404810314698392,"cagr_revenue":0.06802445163796333,"cagr_net_profit":-0.024824727859939055,"cagr_investments":0.08340870897130026,"cagr_firms":0.012540491385266694,"profit_margin_std_3y":0.05289581530397119,"size_index":1.433644181429079,"growth_index":36.85742792437388,"profit_index":71.89766165622677,"risk_index":78.29304685878395,"outlook_index":32.54277018189314,"current_index":50.963415289071165,"future_index":47.562250507704604,"main_index":49.602949376524535,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"01f4a13e-fe9b-4b1d-b4df-f4b0cc3f6231","date":"2016","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2016","revenue":34566.7,"net_profit":2555.7799999999997,"investments":984.72,"firms":218,"profitable_firms":188,"profit_margin":0.07393763361848253,"profitable_share":0.8623853211009175,"bank_debt":4934.73,"total_liab":12272.82,"leverage_bank_to_rev":0.14275965018355816,"leverage_tot_to_rev":0.3550474879002046,"invest_intensity":0.028487532798907624,"cagr_revenue":0.04319016260313191,"cagr_net_profit":-0.17745557786884614,"cagr_investments":0.10759461947576088,"cagr_firms":0.015775467010486377,"profit_margin_std_3y":0.020097481607402407,"size_index":1.4206854365661588,"growth_index":19.66236304892294,"profit_index":75.03301609103288,"risk_index":90.67464556661488,"outlook_index":28.61546052569707,"current_index":51.160375542286644,"future_index":44.54728679494018,"main_index":48.515140043348055,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"e388b0cf-63c7-4a08-aaf8-a394bfdaf870","date":"2017","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2017","revenue":34894.17999999999,"net_profit":1474.53,"investments":1258.42,"firms":188,"profitable_firms":154,"profit_margin":0.04225719016752938,"profitable_share":0.8191489361702128,"bank_debt":5930.66,"total_liab":12828.27,"leverage_bank_to_rev":0.16996129440496957,"leverage_tot_to_rev":0.36763351366904173,"invest_intensity":0.03606389374961671,"cagr_revenue":0.04141954148174665,"cagr_net_profit":-0.17565012572629646,"cagr_investments":0.16649712171786457,"cagr_firms":-0.03621643058092672,"profit_margin_std_3y":0.01727606308086794,"size_index":1.3210213625848537,"growth_index":34.9315809567166,"profit_index":68.40723194124851,"risk_index":93.15247349881211,"outlook_index":9.622389999439093,"current_index":54.04464954665188,"future_index":42.27417233643425,"main_index":49.33645866256482,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"d12a757a-4c1c-4269-8794-eb200fff3f25","date":"2018","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2018","revenue":29248.589999999997,"net_profit":2416.4,"investments":1620.95,"firms":186,"profitable_firms":152,"profit_margin":0.08261594832434659,"profitable_share":0.8172043010752689,"bank_debt":4315.85,"total_liab":11983.939999999999,"leverage_bank_to_rev":0.14755754038057906,"leverage_tot_to_rev":0.40972710137480134,"invest_intensity":0.05541976553399669,"cagr_revenue":-0.04976516711046375,"cagr_net_profit":0.15376227461718783,"cagr_investments":0.117776222681101,"cagr_firms":-0.051540443258264235,"profit_margin_std_3y":0.021243795185667415,"size_index":1.1326888402301658,"growth_index":6.383601551384994,"profit_index":83.08077509971716,"risk_index":90.84069094560209,"outlook_index":12.140604517883098,"current_index":49.8448392145022,"future_index":34.023529556249365,"main_index":43.516315351201065,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"5c00b50e-8f48-43a5-afce-a44f6b71b235","date":"2019","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2019","revenue":30131.82,"net_profit":2254.6800000000003,"investments":1617.28,"firms":188,"profitable_firms":146,"profit_margin":0.07482720924258808,"profitable_share":0.776595744680851,"bank_debt":5907.61,"total_liab":14081.98,"leverage_bank_to_rev":0.19605885074316784,"leverage_tot_to_rev":0.4673458158186263,"invest_intensity":0.05367349200944384,"cagr_revenue":-0.04473804551012128,"cagr_net_profit":-0.04092225152282547,"cagr_investments":0.17984281579644978,"cagr_firms":-0.0481530589453153,"profit_margin_std_3y":0.021409888521404696,"size_index":1.1453348462508253,"growth_index":43.35196598300479,"profit_index":77.1338408787386,"risk_index":89.788068078279,"outlook_index":22.114536692087896,"current_index":57.28693910816971,"future_index":48.7878248952203,"main_index":53.88729342298994,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"5ca5269c-3836-4576-a1d5-81b893f0ca00","date":"2020","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2020","revenue":32651.129999999997,"net_profit":5869.5,"investments":1628.72,"firms":184,"profitable_firms":150,"profit_margin":0.17976406942118084,"profitable_share":0.8152173913043478,"bank_debt":5159.36,"total_liab":11964.73,"leverage_bank_to_rev":0.15801474558460918,"leverage_tot_to_rev":0.3664415289761794,"invest_intensity":0.04988250023812346,"cagr_revenue":-0.02190342153424296,"cagr_net_profit":0.584829322866153,"cagr_investments":0.08978361131863077,"cagr_firms":-0.007143100983618922,"profit_margin_std_3y":0.05846675196678081,"size_index":1.2053128229915364,"growth_index":15.944352819135943,"profit_index":93.36561693646632,"risk_index":87.29771574390806,"outlook_index":27.203188575121285,"current_index":53.75786972667129,"future_index":41.85389599896171,"main_index":48.99628023558746,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"37a6567f-9872-4358-bb21-dcba4e4150e4","date":"2021","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2021","revenue":35260.5,"net_profit":4945.82,"investments":1518.79,"firms":180,"profitable_firms":146,"profit_margin":0.1402651692403681,"profitable_share":0.8111111111111111,"bank_debt":5565.87,"total_liab":12338.46,"leverage_bank_to_rev":0.157850002127026,"leverage_tot_to_rev":0.34992300165908025,"invest_intensity":0.04307341075707945,"cagr_revenue":0.0642929301131554,"cagr_net_profit":0.26966698392448496,"cagr_investments":-0.021465737377266758,"cagr_firms":-0.010870426164858005,"profit_margin_std_3y":0.05300005400674355,"size_index":1.12419510481071,"growth_index":40.52878187764857,"profit_index":74.7070391609982,"risk_index":90.78919648272765,"outlook_index":16.916224349744756,"current_index":56.27055322544213,"future_index":46.16188324801077,"main_index":52.227085234469584,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"2554463a-6094-4d47-bb39-69c2e6b2c8ec","date":"2022","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2022","revenue":46831.34,"net_profit":5937.610000000001,"investments":1786.1799999999998,"firms":174,"profitable_firms":144,"profit_margin":0.1267871045329901,"profitable_share":0.8275862068965517,"bank_debt":5599.349999999999,"total_liab":15018.68,"leverage_bank_to_rev":0.11956416365621825,"leverage_tot_to_rev":0.320697208322461,"invest_intensity":0.03814069808807521,"cagr_revenue":0.15834271959595236,"cagr_net_profit":0.38094246699479695,"cagr_investments":0.0336654542185133,"cagr_firms":-0.025465691640183197,"profit_margin_std_3y":0.027532950418588373,"size_index":1.1461637926883383,"growth_index":34.16848721099244,"profit_index":80.57554377730405,"risk_index":94.14207394168366,"outlook_index":12.820691302760833,"current_index":57.15786268811689,"future_index":43.62144486690716,"main_index":51.743295559633,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"9e8ca75a-9bc2-40a9-ae2a-eb8285db4654","date":"2023","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2023","revenue":25562.69,"net_profit":3318.76,"investments":1444.62,"firms":176,"profitable_firms":70,"profit_margin":0.12982827707099684,"profitable_share":0.3977272727272727,"bank_debt":3288.59,"total_liab":8701.6,"leverage_bank_to_rev":0.1286480413446316,"leverage_tot_to_rev":0.34040235984554057,"invest_intensity":0.056512831787264954,"cagr_revenue":-0.07834274565203891,"cagr_net_profit":-0.1730899948320902,"cagr_investments":-0.03919394514856189,"cagr_firms":-0.014708018867451211,"profit_margin_std_3y":0.0070691309793269284,"size_index":0.8457163692452496,"growth_index":40.050348788806545,"profit_index":57.69659947966312,"risk_index":96.24006402220668,"outlook_index":14.745169096768107,"current_index":53.47789954762847,"future_index":46.78519148201121,"main_index":50.80081632138156,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"9fff522f-7d4a-4ee7-879c-1aebf27011e6","date":"2024","pkd":"21","pkd_name":"PRODUKCJA PODSTAWOWYCH SUBSTANCJI FARMACEUTYCZNYCH ORAZ LEKÓW I POZOSTAŁYCH WYROBÓW FARMACEUTYCZNYCH","year":"2024","revenue":51310.44,"net_profit":7357.92,"investments":2448.29,"firms":178,"profitable_firms":138,"profit_margin":0.1434000565966692,"profitable_share":0.7752808988764045,"bank_debt":5102.13,"total_liab":14972.400000000001,"leverage_bank_to_rev":0.09943648894844792,"leverage_tot_to_rev":0.2918002652091855,"invest_intensity":0.0477152407969996,"cagr_revenue":0.13319789076824118,"cagr_net_profit":0.14157798528210463,"cagr_investments":0.17252391629808983,"cagr_firms":-0.003717506432648343,"profit_margin_std_3y":0.008845263385653414,"size_index":1.2884911242496293,"growth_index":66.51275438418305,"profit_index":86.76967598029705,"risk_index":97.24696499497176,"outlook_index":21.549779773126918,"current_index":67.75239531446148,"future_index":57.74782772299721,"main_index":63.75056827787577,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"f2510b7b-23b7-4913-9698-0b81f8d4476c","date":"2025","pkd":"21","pkd_name":"","year":"2025","revenue":null,"net_profit":null,"investments":null,"firms":null,"profitable_firms":null,"profit_margin":null,"profitable_share":null,"bank_debt":null,"total_liab":null,"leverage_bank_to_rev":null,"leverage_tot_to_rev":null,"invest_intensity":null,"cagr_revenue":null,"cagr_net_profit":null,"cagr_investments":null,"cagr_firms":null,"profit_margin_std_3y":null,"size_index":null,"growth_index":null,"profit_index":null,"risk_index":null,"outlook_index":null,"current_index":null,"future_index":null,"main_index":49.50457718068628,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"020a5fc4-cc8d-405c-a340-74ad7ea43339","date":"2026","pkd":"21","pkd_name":"","year":"2026","revenue":null,"net_profit":null,"investments":null,"firms":null,"profitable_firms":null,"profit_margin":null,"profitable_share":null,"bank_debt":null,"total_liab":null,"leverage_bank_to_rev":null,"leverage_tot_to_rev":null,"invest_intensity":null,"cagr_revenue":null,"cagr_net_profit":null,"cagr_investments":null,"cagr_firms":null,"profit_margin_std_3y":null,"size_index":null,"growth_index":null,"profit_index":null,"risk_index":null,"outlook_index":null,"current_index":null,"future_index":null,"main_index":50.1803678910037,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null},{"id":"2f95a460-4a6c-45ec-9f56-c25386b533c5","date":"2027","pkd":"21","pkd_name":"","year":"2027","revenue":null,"net_profit":null,"investments":null,"firms":null,"profitable_firms":null,"profit_margin":null,"profitable_share":null,"bank_debt":null,"total_liab":null,"leverage_bank_to_rev":null,"leverage_tot_to_rev":null,"invest_intensity":null,"cagr_revenue":null,"cagr_net_profit":null,"cagr_investments":null,"cagr_firms":null,"profit_margin_std_3y":null,"size_index":null,"growth_index":null,"profit_index":null,"risk_index":null,"outlook_index":null,"current_index":null,"future_index":null,"main_index":50.85615860132134,"class1":null,"revenue_parameter":null,"firms_parameter":null,"growth_parameter":null,"cagr_revenue_parameter":null,"cagr_net_profit_parameter":null,"profit_margin_parameter":null,"profitable_share_parameter":null,"leverage_bank_to_rev_parameter":null,"leverage_tot_to_rev_parameter":null,"profit_margin_std_3y_parameter":null,"invest_intensity_parameter":null,"cagr_investments_parameter":null,"size_index_parameter":null,"growth_index_parameter":null,"profit_index_parameter":null,"risk_index_parameter":null,"growth_index_parameter2":null,"profit_index_parameter2":null,"risk_index_parameter2":null,"future_growth_index_parameter":null,"outlook_index_parameter":null,"future_risk_index_parameter":null,"current_index_parameter":null,"future_index_parameter":null,"prediction":null}]